Drug Profile


Alternative Names: SKL-11197; SKL-NP

Latest Information Update: 20 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SK biopharmaceuticals; SK Life Science
  • Developer SK Life Science
  • Class Analgesics
  • Mechanism of Action 12-lipoxygenase inhibitors; 15-lipoxygenase inhibitors; Calcium channel modulators; Hyperpolarisation-activated cation channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies

Most Recent Events

  • 30 Jun 2015 Discontinued - Phase-II for Diabetic neuropathies in USA (PO)
  • 01 Jun 2013 SK Life Science completes a phase II trial in Neuropathic pain (diabetic peripheral neuropathy) in USA (NCT01521598)
  • 19 Feb 2013 SK Life Science completes enrolment in a phase II trial in Neuropathic pain (diabetic peripheral neuropathy) in USA (NCT01521598)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top